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Abstract 
The t(5;17)(q33;p13) rearrangement has been 
observed as sole cytogenetic abnormality in one case 
of chronic myelomonocytic leukemia, a soft-tissue 
aneurysmal bone cyst, and a case of myeloid and 
lymphoid neoplasms (MLNs) with eosinophilia. 
Rare occurrence of lymphoid and mixed MLNs with 
abnormalities of PDGFRB has been reported in two 
cases. The t(5;17)(q33;p13) generates a fusion gene, 
located on the rearranged chromosome 5, comprised 
of the 5' portion of RABEP1 (encoding the coiled-
coil domain) and the 3' portion of PDGFRB 
(encoding the intracellular kinase domain). 
Expression of the resulting fusion protein has been 
demonstrated to cause myeloproliferative disease in 
mice. 
Clinics and pathology 
Disease 
Chronic myelomonocytic leukemia (CMML) and 
myeloid and lymphoid neoplasm (MLN) with mixed 
myeloproliferative/myelodysplastic features and (T-
LBL). 
Note 
One case of aneurysmal bone cyst with 
t(5;17)(q33;p13) RABEP1/PDGFRB has also been 
described.  
Ondrejka et al., 2014 also reports a second case of 
MLN with eosinophilia and PDGFRB 
rearrangement, a 38 year old male. This patient 
exhibited T-LBL and an unclassifiable 
myeloproliferative neoplasm.  A sole cytogenetic 
abnormality, t(5;6)(q22;q21), was observed. 
Molecular studies revealed a novel C6orf204-
PDGFRB fusion. 
t(5;17)(q33;p13) in G-banded chromosome 
Phenotype/cell stem origin 
Pluripotent hematopoetic stem cell in the MLN case. 
Epidemiology 
One case of CMML with t(5;17)(q33;p13) to date: a 
male patient aged 29 at diagnosis (Magnusson et al., 
2001 and Magnusson et al., 2002) and one case of 
t(5;17)(q33;p13) in MLN with mixed features and T-
LBL : male, 64 years of age at diagnosis (Ondrejka 
et al., 2014). 
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Clinics 
Massive splenomegaly, anemia, mild 
thrombocytopenia, leukocytosis comprised 
primarily of neutrophils and monocytes in the 
CMML patient (Magnusson et al., 2001, Magnusson 
et al., 2002); splenomegaly and diffuse adenopathy, 
anemia, thrombocytopenia, mild eosinophilia in the 
MLN patient (Ondrejka et al., 2014). 
Cytology 
CMML case: hypercellular bone marrow with left 
shift (Magnusson et al., 2001). 
Pathology 
MLN case: T lymphoblasts were positive by flow 
cytometery for CD1a, CD2, CD3, CD4, CD5, CD7, 
CD8, CD10, CD38, and CD45.   
Bone marrow biopsy was hypercellular and 
demonstrated features of a myeloid neoplasm with 
mixed myeloproliferative/myelodysplastic features 
and no T-LBL involvement.   
Marrow displayed abnormal granulocytic 
maturation, mild dyserythropoiesis, and atypical, 
small megakaryocytes (Ondrejka et al., 2014). 
Treatment 
CMML case: Allogeneic stem cell transplant from 
HLA-matched sibling (Magnusson et al., 2002).  
Relapsed 15 months after SCT. Received STI571 
treatment and achieved molecular remission by 6 
weeks, which was maintained for 6 months at time 
of report (Magnusson et al., 2002).  
MLN case: Vincristine/prednisone-based induction. 
Imatinib treatment for 18 days, then ceased due to 
drug intolerance.  Patient opted for hospice care 
(Ondrejka et al., 2014). 
Cytogenetics 
Cytogenetics morphological 
Cytogenetic analysis has revealed t(5;17)(q33;p13) 
as a sole abnormality. 
Cytogenetics molecular 
Metaphase FISH analysis with PDGFRB break apart 
probe reveals rearrangement of 5q33, interphase 
FISH with probe encompassing RABEP1 locus 
reveals rearrangement of 17p13. 
Probes 
LPH031-A, CytoCell, Cambridge, UK.  RP11-
457I18, Blue Gnome, Cambridge, UK. 
Additional anomalies 
Reported only as a sole anomaly. 
Variants 
PDGFRB is involved in rearrangements with 
numerous other translocation partners. 
Genes involved and 
proteins 
PDGFRB 
Location 5q33; chr5:150,113,839-150,155,859 
(hg38) 
DNA/RNA 
Gene is 42 kb and contains 26 exons.  Transcription 
occurs in telomere to centromere orientation.  5 
transcripts are reported. 
Protein 
PDGRFB encodes a tyrosine kinase receptor that is 
located on the plasma membrane and is activated by 
binding of members of the platelet-derived growth 
factor family of proteins.  
The product of the largest transcript is 1106 amino 
acids. Composed from NH2 to COOH of: Ig-like 
extracellular domains, a transmembrane domain, and 
a cytosolic tyrosine kinase domain. 
RABEP1 
Location 17p13.2; chr17: 5,282,263-5,385,812 
(hg38) 
DNA/RNA 
Gene is 103 kb and contains 20 exons.  Transcription 
occurs in centromere to telomere orientation.  6 
transcripts are reported. 
Protein 
RABEP1 encodes a protein involved in endocytic 
membrane fusion and the trafficking of recycling 
endosomes.   
The product of the largest transcript is 826 amino 
acids and contains coiled-coil domains, a NH2-
terminal RAB4 binding site, and a COOH-terminal 
RAB5 binding site. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5' RABEP1- 3' PDGFRb; no reciprocal transcript. 
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A schematic of the fusion transcript generated by the t(5;17)(q33;p13) rearrangement. Modified from Magnusson et al., 2001 
 
Fusion protein 
Description 
1318 amino acid fusion protein, including the first 
739 aa of RABEP1 fused to the transmembrane and 
cytosolic tyrosine kinase domains of PDGFRB. 
Oncogenesis 
Expression of the fusion protein via infection with a 
MSCV-based retroviral plasmid was sufficient to 
transform Ba/F3 cells such that they grew 
independent of IL-3 (Magnusson et al., 2001). 
Expression of the fusion gene in murine bone 
marrow cells transplanted into lethally irradiated 
mice caused development of fatal myeloproliferative 
disorder (Magnusson et al., 2001). 
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